Pfizer Adcetris — Revenues: decreased by 13.6% to $190.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.8%, from $218.00M to $190.00M.
pfe_segment_adcetris_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $56.00M | $257.00M | $279.00M | $268.00M | $285.00M | $218.00M | $255.00M | $215.00M | $220.00M | $190.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | +358.9% | +8.6% | -3.9% | +6.3% | -23.5% | +17.0% | -15.7% | +2.3% | -13.6% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +408.9% | -15.2% | -8.6% | -19.8% | -22.8% | -12.8% |